nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—ADRA1D—epithelium—ovarian cancer	0.0032	0.0642	CbGeAlD
Dexmedetomidine—ADRA1D—female reproductive system—ovarian cancer	0.00238	0.0477	CbGeAlD
Dexmedetomidine—ADRA2C—myometrium—ovarian cancer	0.00223	0.0448	CbGeAlD
Dexmedetomidine—SLC6A2—decidua—ovarian cancer	0.00187	0.0375	CbGeAlD
Dexmedetomidine—ADRA2A—myometrium—ovarian cancer	0.00178	0.0357	CbGeAlD
Dexmedetomidine—ADRA2C—uterine cervix—ovarian cancer	0.00174	0.0348	CbGeAlD
Dexmedetomidine—ADRA2C—decidua—ovarian cancer	0.00165	0.0332	CbGeAlD
Dexmedetomidine—SLC6A2—gonad—ovarian cancer	0.00164	0.033	CbGeAlD
Dexmedetomidine—ADRA2C—endometrium—ovarian cancer	0.00157	0.0315	CbGeAlD
Dexmedetomidine—Body temperature increased—Chlorambucil—ovarian cancer	0.00156	0.00172	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Paclitaxel—ovarian cancer	0.00155	0.00172	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Paclitaxel—ovarian cancer	0.00155	0.00172	CcSEcCtD
Dexmedetomidine—Atrioventricular block—Doxorubicin—ovarian cancer	0.00154	0.00171	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Paclitaxel—ovarian cancer	0.00154	0.0017	CcSEcCtD
Dexmedetomidine—Fluid retention—Epirubicin—ovarian cancer	0.00153	0.0017	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Docetaxel—ovarian cancer	0.00153	0.0017	CcSEcCtD
Dexmedetomidine—Dyspnoea—Melphalan—ovarian cancer	0.00153	0.0017	CcSEcCtD
Dexmedetomidine—Blood urea increased—Epirubicin—ovarian cancer	0.00153	0.00169	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00151	0.00168	CcSEcCtD
Dexmedetomidine—Pain—Topotecan—ovarian cancer	0.0015	0.00166	CcSEcCtD
Dexmedetomidine—Constipation—Topotecan—ovarian cancer	0.0015	0.00166	CcSEcCtD
Dexmedetomidine—CYP1A1—epithelium—ovarian cancer	0.0015	0.0301	CbGeAlD
Dexmedetomidine—Phosphatase alkaline increased—Doxorubicin—ovarian cancer	0.0015	0.00166	CcSEcCtD
Dexmedetomidine—Ventricular tachycardia—Doxorubicin—ovarian cancer	0.0015	0.00166	CcSEcCtD
Dexmedetomidine—Infection—Vinorelbine—ovarian cancer	0.00149	0.00165	CcSEcCtD
Dexmedetomidine—CYP1A1—uterine cervix—ovarian cancer	0.00149	0.0298	CbGeAlD
Dexmedetomidine—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00148	0.00164	CcSEcCtD
Dexmedetomidine—Bronchospasm—Docetaxel—ovarian cancer	0.00148	0.00164	CcSEcCtD
Dexmedetomidine—Hyperkalaemia—Doxorubicin—ovarian cancer	0.00147	0.00163	CcSEcCtD
Dexmedetomidine—SLC6A2—female reproductive system—ovarian cancer	0.00147	0.0295	CbGeAlD
Dexmedetomidine—Thrombocytopenia—Vinorelbine—ovarian cancer	0.00147	0.00163	CcSEcCtD
Dexmedetomidine—Pain—Melphalan—ovarian cancer	0.00147	0.00163	CcSEcCtD
Dexmedetomidine—Tachycardia—Vinorelbine—ovarian cancer	0.00146	0.00162	CcSEcCtD
Dexmedetomidine—ADRA2C—uterus—ovarian cancer	0.00145	0.029	CbGeAlD
Dexmedetomidine—Bradycardia—Paclitaxel—ovarian cancer	0.00145	0.0016	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Topotecan—ovarian cancer	0.00144	0.0016	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Epirubicin—ovarian cancer	0.00144	0.00159	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Topotecan—ovarian cancer	0.00143	0.00159	CcSEcCtD
Dexmedetomidine—Haemoglobin—Paclitaxel—ovarian cancer	0.00143	0.00158	CcSEcCtD
Dexmedetomidine—Fluid retention—Doxorubicin—ovarian cancer	0.00142	0.00157	CcSEcCtD
Dexmedetomidine—Haemorrhage—Paclitaxel—ovarian cancer	0.00142	0.00157	CcSEcCtD
Dexmedetomidine—Blood urea increased—Doxorubicin—ovarian cancer	0.00141	0.00156	CcSEcCtD
Dexmedetomidine—Abnormal vision—Epirubicin—ovarian cancer	0.00141	0.00156	CcSEcCtD
Dexmedetomidine—Sepsis—Epirubicin—ovarian cancer	0.0014	0.00155	CcSEcCtD
Dexmedetomidine—Hypotension—Vinorelbine—ovarian cancer	0.0014	0.00155	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Paclitaxel—ovarian cancer	0.0014	0.00155	CcSEcCtD
Dexmedetomidine—Abdominal pain—Topotecan—ovarian cancer	0.00139	0.00154	CcSEcCtD
Dexmedetomidine—Body temperature increased—Topotecan—ovarian cancer	0.00139	0.00154	CcSEcCtD
Dexmedetomidine—ADRA2A—uterine cervix—ovarian cancer	0.00139	0.0278	CbGeAlD
Dexmedetomidine—Visual impairment—Paclitaxel—ovarian cancer	0.00137	0.00152	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Epirubicin—ovarian cancer	0.00135	0.00149	CcSEcCtD
Dexmedetomidine—Pneumonia—Docetaxel—ovarian cancer	0.00135	0.00149	CcSEcCtD
Dexmedetomidine—Diarrhoea—Chlorambucil—ovarian cancer	0.00135	0.00149	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Epirubicin—ovarian cancer	0.00134	0.00149	CcSEcCtD
Dexmedetomidine—Dyspnoea—Vinorelbine—ovarian cancer	0.00134	0.00148	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Doxorubicin—ovarian cancer	0.00133	0.00147	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Docetaxel—ovarian cancer	0.00132	0.00146	CcSEcCtD
Dexmedetomidine—ADRA2A—decidua—ovarian cancer	0.00132	0.0265	CbGeAlD
Dexmedetomidine—Cardiac disorder—Paclitaxel—ovarian cancer	0.00132	0.00146	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Docetaxel—ovarian cancer	0.00131	0.00146	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Docetaxel—ovarian cancer	0.00131	0.00146	CcSEcCtD
Dexmedetomidine—Abnormal vision—Doxorubicin—ovarian cancer	0.0013	0.00144	CcSEcCtD
Dexmedetomidine—Sepsis—Doxorubicin—ovarian cancer	0.0013	0.00144	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00129	0.00143	CcSEcCtD
Dexmedetomidine—Angiopathy—Paclitaxel—ovarian cancer	0.00129	0.00143	CcSEcCtD
Dexmedetomidine—Pain—Vinorelbine—ovarian cancer	0.00128	0.00142	CcSEcCtD
Dexmedetomidine—Constipation—Vinorelbine—ovarian cancer	0.00128	0.00142	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Paclitaxel—ovarian cancer	0.00128	0.00142	CcSEcCtD
Dexmedetomidine—Chills—Paclitaxel—ovarian cancer	0.00127	0.00141	CcSEcCtD
Dexmedetomidine—Renal failure acute—Epirubicin—ovarian cancer	0.00127	0.00141	CcSEcCtD
Dexmedetomidine—Arrhythmia—Paclitaxel—ovarian cancer	0.00127	0.00141	CcSEcCtD
Dexmedetomidine—ADRA2A—endometrium—ovarian cancer	0.00125	0.0251	CbGeAlD
Dexmedetomidine—Vomiting—Chlorambucil—ovarian cancer	0.00125	0.00139	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Doxorubicin—ovarian cancer	0.00125	0.00138	CcSEcCtD
Dexmedetomidine—Mental disorder—Paclitaxel—ovarian cancer	0.00124	0.00138	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Doxorubicin—ovarian cancer	0.00124	0.00138	CcSEcCtD
Dexmedetomidine—CYP1A1—uterus—ovarian cancer	0.00124	0.0248	CbGeAlD
Dexmedetomidine—Malnutrition—Paclitaxel—ovarian cancer	0.00124	0.00137	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Vinorelbine—ovarian cancer	0.00124	0.00137	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00123	0.00136	CcSEcCtD
Dexmedetomidine—Haemoglobin—Docetaxel—ovarian cancer	0.00121	0.00134	CcSEcCtD
Dexmedetomidine—Haemorrhage—Docetaxel—ovarian cancer	0.0012	0.00133	CcSEcCtD
Dexmedetomidine—Hypoglycaemia—Epirubicin—ovarian cancer	0.0012	0.00133	CcSEcCtD
Dexmedetomidine—Diarrhoea—Topotecan—ovarian cancer	0.0012	0.00133	CcSEcCtD
Dexmedetomidine—Abdominal pain—Vinorelbine—ovarian cancer	0.00119	0.00131	CcSEcCtD
Dexmedetomidine—Body temperature increased—Vinorelbine—ovarian cancer	0.00119	0.00131	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Docetaxel—ovarian cancer	0.00119	0.00131	CcSEcCtD
Dexmedetomidine—SLC6A2—testis—ovarian cancer	0.00118	0.0238	CbGeAlD
Dexmedetomidine—ADRA2C—female gonad—ovarian cancer	0.00118	0.0237	CbGeAlD
Dexmedetomidine—ADRA2C—vagina—ovarian cancer	0.00118	0.0236	CbGeAlD
Dexmedetomidine—Renal failure acute—Doxorubicin—ovarian cancer	0.00118	0.0013	CcSEcCtD
Dexmedetomidine—Diarrhoea—Melphalan—ovarian cancer	0.00117	0.0013	CcSEcCtD
Dexmedetomidine—Nausea—Chlorambucil—ovarian cancer	0.00117	0.0013	CcSEcCtD
Dexmedetomidine—ADRA2A—gonad—ovarian cancer	0.00116	0.0233	CbGeAlD
Dexmedetomidine—Visual impairment—Docetaxel—ovarian cancer	0.00116	0.00128	CcSEcCtD
Dexmedetomidine—Dizziness—Topotecan—ovarian cancer	0.00116	0.00128	CcSEcCtD
Dexmedetomidine—ADRA2A—uterus—ovarian cancer	0.00115	0.0232	CbGeAlD
Dexmedetomidine—Anaemia—Paclitaxel—ovarian cancer	0.00114	0.00127	CcSEcCtD
Dexmedetomidine—Agitation—Paclitaxel—ovarian cancer	0.00114	0.00126	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Docetaxel—ovarian cancer	0.00112	0.00124	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Epirubicin—ovarian cancer	0.00112	0.00124	CcSEcCtD
Dexmedetomidine—Vomiting—Topotecan—ovarian cancer	0.00111	0.00123	CcSEcCtD
Dexmedetomidine—CYP1A1—female reproductive system—ovarian cancer	0.00111	0.0223	CbGeAlD
Dexmedetomidine—Hypoglycaemia—Doxorubicin—ovarian cancer	0.00111	0.00123	CcSEcCtD
Dexmedetomidine—Rash—Topotecan—ovarian cancer	0.00111	0.00122	CcSEcCtD
Dexmedetomidine—Dermatitis—Topotecan—ovarian cancer	0.0011	0.00122	CcSEcCtD
Dexmedetomidine—Headache—Topotecan—ovarian cancer	0.0011	0.00122	CcSEcCtD
Dexmedetomidine—Angiopathy—Docetaxel—ovarian cancer	0.00109	0.00121	CcSEcCtD
Dexmedetomidine—Vomiting—Melphalan—ovarian cancer	0.00109	0.00121	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Docetaxel—ovarian cancer	0.00108	0.0012	CcSEcCtD
Dexmedetomidine—Rash—Melphalan—ovarian cancer	0.00108	0.0012	CcSEcCtD
Dexmedetomidine—Dermatitis—Melphalan—ovarian cancer	0.00108	0.0012	CcSEcCtD
Dexmedetomidine—Chills—Docetaxel—ovarian cancer	0.00108	0.0012	CcSEcCtD
Dexmedetomidine—Arrhythmia—Docetaxel—ovarian cancer	0.00107	0.00119	CcSEcCtD
Dexmedetomidine—Convulsion—Paclitaxel—ovarian cancer	0.00107	0.00119	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Epirubicin—ovarian cancer	0.00107	0.00118	CcSEcCtD
Dexmedetomidine—Hypertension—Paclitaxel—ovarian cancer	0.00107	0.00118	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.00106	0.00117	CcSEcCtD
Dexmedetomidine—Mental disorder—Docetaxel—ovarian cancer	0.00105	0.00117	CcSEcCtD
Dexmedetomidine—ADRA2C—testis—ovarian cancer	0.00105	0.0211	CbGeAlD
Dexmedetomidine—Anxiety—Paclitaxel—ovarian cancer	0.00105	0.00116	CcSEcCtD
Dexmedetomidine—Malnutrition—Docetaxel—ovarian cancer	0.00105	0.00116	CcSEcCtD
Dexmedetomidine—Nausea—Topotecan—ovarian cancer	0.00104	0.00115	CcSEcCtD
Dexmedetomidine—ADRA2A—female reproductive system—ovarian cancer	0.00104	0.0208	CbGeAlD
Dexmedetomidine—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.00103	0.00115	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Doxorubicin—ovarian cancer	0.00103	0.00114	CcSEcCtD
Dexmedetomidine—Dry mouth—Paclitaxel—ovarian cancer	0.00103	0.00114	CcSEcCtD
Dexmedetomidine—Diarrhoea—Vinorelbine—ovarian cancer	0.00103	0.00114	CcSEcCtD
Dexmedetomidine—Abdominal distension—Epirubicin—ovarian cancer	0.00102	0.00113	CcSEcCtD
Dexmedetomidine—Nausea—Melphalan—ovarian cancer	0.00102	0.00113	CcSEcCtD
Dexmedetomidine—Confusional state—Paclitaxel—ovarian cancer	0.00102	0.00113	CcSEcCtD
Dexmedetomidine—CYP2E1—female reproductive system—ovarian cancer	0.00102	0.0204	CbGeAlD
Dexmedetomidine—CYP1A1—female gonad—ovarian cancer	0.00101	0.0203	CbGeAlD
Dexmedetomidine—CYP1A1—vagina—ovarian cancer	0.00101	0.0202	CbGeAlD
Dexmedetomidine—Infection—Paclitaxel—ovarian cancer	0.001	0.00111	CcSEcCtD
Dexmedetomidine—Dizziness—Vinorelbine—ovarian cancer	0.000992	0.0011	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Doxorubicin—ovarian cancer	0.000988	0.00109	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000987	0.00109	CcSEcCtD
Dexmedetomidine—Tachycardia—Paclitaxel—ovarian cancer	0.000984	0.00109	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000977	0.00108	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000975	0.00108	CcSEcCtD
Dexmedetomidine—Anaemia—Docetaxel—ovarian cancer	0.000968	0.00107	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000957	0.00106	CcSEcCtD
Dexmedetomidine—Vomiting—Vinorelbine—ovarian cancer	0.000953	0.00106	CcSEcCtD
Dexmedetomidine—Rash—Vinorelbine—ovarian cancer	0.000945	0.00105	CcSEcCtD
Dexmedetomidine—Dermatitis—Vinorelbine—ovarian cancer	0.000945	0.00105	CcSEcCtD
Dexmedetomidine—Abdominal distension—Doxorubicin—ovarian cancer	0.000944	0.00105	CcSEcCtD
Dexmedetomidine—ADRA2A—female gonad—ovarian cancer	0.000944	0.0189	CbGeAlD
Dexmedetomidine—Hypotension—Paclitaxel—ovarian cancer	0.000942	0.00104	CcSEcCtD
Dexmedetomidine—Headache—Vinorelbine—ovarian cancer	0.000939	0.00104	CcSEcCtD
Dexmedetomidine—ADRA2A—vagina—ovarian cancer	0.000939	0.0188	CbGeAlD
Dexmedetomidine—Hyperglycaemia—Epirubicin—ovarian cancer	0.000915	0.00101	CcSEcCtD
Dexmedetomidine—Pneumonia—Epirubicin—ovarian cancer	0.000909	0.00101	CcSEcCtD
Dexmedetomidine—Convulsion—Docetaxel—ovarian cancer	0.000908	0.00101	CcSEcCtD
Dexmedetomidine—Hypertension—Docetaxel—ovarian cancer	0.000904	0.001	CcSEcCtD
Dexmedetomidine—Dyspnoea—Paclitaxel—ovarian cancer	0.000899	0.000996	CcSEcCtD
Dexmedetomidine—Somnolence—Paclitaxel—ovarian cancer	0.000897	0.000993	CcSEcCtD
Dexmedetomidine—Nausea—Vinorelbine—ovarian cancer	0.000891	0.000987	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000886	0.000982	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Epirubicin—ovarian cancer	0.000879	0.000974	CcSEcCtD
Dexmedetomidine—Dry mouth—Docetaxel—ovarian cancer	0.000872	0.000966	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000871	0.000965	CcSEcCtD
Dexmedetomidine—Pain—Paclitaxel—ovarian cancer	0.000862	0.000956	CcSEcCtD
Dexmedetomidine—Constipation—Paclitaxel—ovarian cancer	0.000862	0.000956	CcSEcCtD
Dexmedetomidine—Confusional state—Docetaxel—ovarian cancer	0.000862	0.000955	CcSEcCtD
Dexmedetomidine—SLC6A2—lymph node—ovarian cancer	0.000859	0.0172	CbGeAlD
Dexmedetomidine—Infection—Docetaxel—ovarian cancer	0.000849	0.000941	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000846	0.000938	CcSEcCtD
Dexmedetomidine—Pneumonia—Doxorubicin—ovarian cancer	0.000841	0.000932	CcSEcCtD
Dexmedetomidine—ADRA2A—testis—ovarian cancer	0.000838	0.0168	CbGeAlD
Dexmedetomidine—Thrombocytopenia—Docetaxel—ovarian cancer	0.000837	0.000927	CcSEcCtD
Dexmedetomidine—Tachycardia—Docetaxel—ovarian cancer	0.000834	0.000924	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000831	0.000921	CcSEcCtD
Dexmedetomidine—Bradycardia—Epirubicin—ovarian cancer	0.000826	0.000915	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000825	0.000914	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.00082	0.000909	CcSEcCtD
Dexmedetomidine—CYP2E1—testis—ovarian cancer	0.000819	0.0164	CbGeAlD
Dexmedetomidine—Haemoglobin—Epirubicin—ovarian cancer	0.000816	0.000904	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Doxorubicin—ovarian cancer	0.000813	0.000901	CcSEcCtD
Dexmedetomidine—Haemorrhage—Epirubicin—ovarian cancer	0.000812	0.000899	CcSEcCtD
Dexmedetomidine—CYP2D6—female reproductive system—ovarian cancer	0.000804	0.0161	CbGeAlD
Dexmedetomidine—Oedema peripheral—Epirubicin—ovarian cancer	0.0008	0.000886	CcSEcCtD
Dexmedetomidine—Hypotension—Docetaxel—ovarian cancer	0.000799	0.000885	CcSEcCtD
Dexmedetomidine—Body temperature increased—Paclitaxel—ovarian cancer	0.000797	0.000883	CcSEcCtD
Dexmedetomidine—Abdominal pain—Paclitaxel—ovarian cancer	0.000797	0.000883	CcSEcCtD
Dexmedetomidine—Visual impairment—Epirubicin—ovarian cancer	0.000782	0.000867	CcSEcCtD
Dexmedetomidine—Bradycardia—Doxorubicin—ovarian cancer	0.000764	0.000847	CcSEcCtD
Dexmedetomidine—Dyspnoea—Docetaxel—ovarian cancer	0.000762	0.000844	CcSEcCtD
Dexmedetomidine—ADRA2C—lymph node—ovarian cancer	0.000761	0.0153	CbGeAlD
Dexmedetomidine—Somnolence—Docetaxel—ovarian cancer	0.00076	0.000842	CcSEcCtD
Dexmedetomidine—Haemoglobin—Doxorubicin—ovarian cancer	0.000755	0.000836	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Epirubicin—ovarian cancer	0.000753	0.000835	CcSEcCtD
Dexmedetomidine—Haemorrhage—Doxorubicin—ovarian cancer	0.000751	0.000832	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Doxorubicin—ovarian cancer	0.00074	0.00082	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000738	0.000818	CcSEcCtD
Dexmedetomidine—Angiopathy—Epirubicin—ovarian cancer	0.000736	0.000816	CcSEcCtD
Dexmedetomidine—CYP2D6—female gonad—ovarian cancer	0.000732	0.0147	CbGeAlD
Dexmedetomidine—Mediastinal disorder—Epirubicin—ovarian cancer	0.000731	0.00081	CcSEcCtD
Dexmedetomidine—Pain—Docetaxel—ovarian cancer	0.000731	0.00081	CcSEcCtD
Dexmedetomidine—Constipation—Docetaxel—ovarian cancer	0.000731	0.00081	CcSEcCtD
Dexmedetomidine—Chills—Epirubicin—ovarian cancer	0.000728	0.000807	CcSEcCtD
Dexmedetomidine—Arrhythmia—Epirubicin—ovarian cancer	0.000725	0.000803	CcSEcCtD
Dexmedetomidine—Visual impairment—Doxorubicin—ovarian cancer	0.000724	0.000802	CcSEcCtD
Dexmedetomidine—Mental disorder—Epirubicin—ovarian cancer	0.000711	0.000788	CcSEcCtD
Dexmedetomidine—Malnutrition—Epirubicin—ovarian cancer	0.000706	0.000783	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Docetaxel—ovarian cancer	0.000704	0.000781	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000699	0.000775	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Doxorubicin—ovarian cancer	0.000697	0.000772	CcSEcCtD
Dexmedetomidine—Diarrhoea—Paclitaxel—ovarian cancer	0.00069	0.000765	CcSEcCtD
Dexmedetomidine—Angiopathy—Doxorubicin—ovarian cancer	0.000681	0.000755	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000677	0.00075	CcSEcCtD
Dexmedetomidine—Body temperature increased—Docetaxel—ovarian cancer	0.000676	0.000749	CcSEcCtD
Dexmedetomidine—Abdominal pain—Docetaxel—ovarian cancer	0.000676	0.000749	CcSEcCtD
Dexmedetomidine—Chills—Doxorubicin—ovarian cancer	0.000674	0.000747	CcSEcCtD
Dexmedetomidine—Arrhythmia—Doxorubicin—ovarian cancer	0.000671	0.000743	CcSEcCtD
Dexmedetomidine—Dizziness—Paclitaxel—ovarian cancer	0.000667	0.000739	CcSEcCtD
Dexmedetomidine—Mental disorder—Doxorubicin—ovarian cancer	0.000658	0.000729	CcSEcCtD
Dexmedetomidine—Malnutrition—Doxorubicin—ovarian cancer	0.000654	0.000724	CcSEcCtD
Dexmedetomidine—Anaemia—Epirubicin—ovarian cancer	0.000653	0.000723	CcSEcCtD
Dexmedetomidine—CYP1A1—lymph node—ovarian cancer	0.000651	0.0131	CbGeAlD
Dexmedetomidine—Agitation—Epirubicin—ovarian cancer	0.000649	0.000719	CcSEcCtD
Dexmedetomidine—CYP2D6—testis—ovarian cancer	0.000649	0.013	CbGeAlD
Dexmedetomidine—Vomiting—Paclitaxel—ovarian cancer	0.000641	0.00071	CcSEcCtD
Dexmedetomidine—Rash—Paclitaxel—ovarian cancer	0.000636	0.000705	CcSEcCtD
Dexmedetomidine—Dermatitis—Paclitaxel—ovarian cancer	0.000635	0.000704	CcSEcCtD
Dexmedetomidine—Headache—Paclitaxel—ovarian cancer	0.000632	0.0007	CcSEcCtD
Dexmedetomidine—Convulsion—Epirubicin—ovarian cancer	0.000612	0.000678	CcSEcCtD
Dexmedetomidine—Hypertension—Epirubicin—ovarian cancer	0.00061	0.000676	CcSEcCtD
Dexmedetomidine—ADRA2A—lymph node—ovarian cancer	0.000607	0.0122	CbGeAlD
Dexmedetomidine—Anaemia—Doxorubicin—ovarian cancer	0.000604	0.000669	CcSEcCtD
Dexmedetomidine—Agitation—Doxorubicin—ovarian cancer	0.000601	0.000666	CcSEcCtD
Dexmedetomidine—Anxiety—Epirubicin—ovarian cancer	0.000599	0.000664	CcSEcCtD
Dexmedetomidine—Nausea—Paclitaxel—ovarian cancer	0.000599	0.000664	CcSEcCtD
Dexmedetomidine—Dry mouth—Epirubicin—ovarian cancer	0.000588	0.000652	CcSEcCtD
Dexmedetomidine—Diarrhoea—Docetaxel—ovarian cancer	0.000585	0.000648	CcSEcCtD
Dexmedetomidine—Confusional state—Epirubicin—ovarian cancer	0.000581	0.000644	CcSEcCtD
Dexmedetomidine—Infection—Epirubicin—ovarian cancer	0.000573	0.000635	CcSEcCtD
Dexmedetomidine—Convulsion—Doxorubicin—ovarian cancer	0.000566	0.000628	CcSEcCtD
Dexmedetomidine—Dizziness—Docetaxel—ovarian cancer	0.000565	0.000626	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Epirubicin—ovarian cancer	0.000565	0.000626	CcSEcCtD
Dexmedetomidine—Hypertension—Doxorubicin—ovarian cancer	0.000564	0.000625	CcSEcCtD
Dexmedetomidine—Tachycardia—Epirubicin—ovarian cancer	0.000563	0.000624	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Epirubicin—ovarian cancer	0.000557	0.000618	CcSEcCtD
Dexmedetomidine—Anxiety—Doxorubicin—ovarian cancer	0.000555	0.000614	CcSEcCtD
Dexmedetomidine—Dry mouth—Doxorubicin—ovarian cancer	0.000544	0.000603	CcSEcCtD
Dexmedetomidine—Vomiting—Docetaxel—ovarian cancer	0.000544	0.000602	CcSEcCtD
Dexmedetomidine—Rash—Docetaxel—ovarian cancer	0.000539	0.000597	CcSEcCtD
Dexmedetomidine—Hypotension—Epirubicin—ovarian cancer	0.000539	0.000597	CcSEcCtD
Dexmedetomidine—Dermatitis—Docetaxel—ovarian cancer	0.000539	0.000597	CcSEcCtD
Dexmedetomidine—Confusional state—Doxorubicin—ovarian cancer	0.000538	0.000596	CcSEcCtD
Dexmedetomidine—Headache—Docetaxel—ovarian cancer	0.000536	0.000593	CcSEcCtD
Dexmedetomidine—Infection—Doxorubicin—ovarian cancer	0.00053	0.000587	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000522	0.000579	CcSEcCtD
Dexmedetomidine—Tachycardia—Doxorubicin—ovarian cancer	0.000521	0.000577	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000516	0.000571	CcSEcCtD
Dexmedetomidine—Dyspnoea—Epirubicin—ovarian cancer	0.000514	0.00057	CcSEcCtD
Dexmedetomidine—Somnolence—Epirubicin—ovarian cancer	0.000513	0.000568	CcSEcCtD
Dexmedetomidine—Nausea—Docetaxel—ovarian cancer	0.000508	0.000563	CcSEcCtD
Dexmedetomidine—Hypotension—Doxorubicin—ovarian cancer	0.000499	0.000552	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000498	0.000552	CcSEcCtD
Dexmedetomidine—Pain—Epirubicin—ovarian cancer	0.000493	0.000546	CcSEcCtD
Dexmedetomidine—Constipation—Epirubicin—ovarian cancer	0.000493	0.000546	CcSEcCtD
Dexmedetomidine—Dyspnoea—Doxorubicin—ovarian cancer	0.000476	0.000527	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Epirubicin—ovarian cancer	0.000475	0.000526	CcSEcCtD
Dexmedetomidine—Somnolence—Doxorubicin—ovarian cancer	0.000474	0.000526	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000471	0.000522	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000461	0.00051	CcSEcCtD
Dexmedetomidine—Pain—Doxorubicin—ovarian cancer	0.000456	0.000505	CcSEcCtD
Dexmedetomidine—Constipation—Doxorubicin—ovarian cancer	0.000456	0.000505	CcSEcCtD
Dexmedetomidine—Body temperature increased—Epirubicin—ovarian cancer	0.000456	0.000505	CcSEcCtD
Dexmedetomidine—Abdominal pain—Epirubicin—ovarian cancer	0.000456	0.000505	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Doxorubicin—ovarian cancer	0.00044	0.000487	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000436	0.000483	CcSEcCtD
Dexmedetomidine—Abdominal pain—Doxorubicin—ovarian cancer	0.000422	0.000467	CcSEcCtD
Dexmedetomidine—Body temperature increased—Doxorubicin—ovarian cancer	0.000422	0.000467	CcSEcCtD
Dexmedetomidine—Diarrhoea—Epirubicin—ovarian cancer	0.000395	0.000437	CcSEcCtD
Dexmedetomidine—Dizziness—Epirubicin—ovarian cancer	0.000381	0.000422	CcSEcCtD
Dexmedetomidine—Vomiting—Epirubicin—ovarian cancer	0.000367	0.000406	CcSEcCtD
Dexmedetomidine—Diarrhoea—Doxorubicin—ovarian cancer	0.000365	0.000404	CcSEcCtD
Dexmedetomidine—Rash—Epirubicin—ovarian cancer	0.000364	0.000403	CcSEcCtD
Dexmedetomidine—Dermatitis—Epirubicin—ovarian cancer	0.000363	0.000402	CcSEcCtD
Dexmedetomidine—Headache—Epirubicin—ovarian cancer	0.000361	0.0004	CcSEcCtD
Dexmedetomidine—Dizziness—Doxorubicin—ovarian cancer	0.000353	0.000391	CcSEcCtD
Dexmedetomidine—Nausea—Epirubicin—ovarian cancer	0.000342	0.000379	CcSEcCtD
Dexmedetomidine—Vomiting—Doxorubicin—ovarian cancer	0.000339	0.000376	CcSEcCtD
Dexmedetomidine—Rash—Doxorubicin—ovarian cancer	0.000336	0.000373	CcSEcCtD
Dexmedetomidine—Dermatitis—Doxorubicin—ovarian cancer	0.000336	0.000372	CcSEcCtD
Dexmedetomidine—Headache—Doxorubicin—ovarian cancer	0.000334	0.00037	CcSEcCtD
Dexmedetomidine—Nausea—Doxorubicin—ovarian cancer	0.000317	0.000351	CcSEcCtD
Dexmedetomidine—CYP2D6—Metabolism—CYP1B1—ovarian cancer	1.42e-05	0.000298	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—IL2—ovarian cancer	1.42e-05	0.000298	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.41e-05	0.000296	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ESR1—ovarian cancer	1.41e-05	0.000295	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PIK3CB—ovarian cancer	1.4e-05	0.000294	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CD—ovarian cancer	1.4e-05	0.000294	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CD—ovarian cancer	1.39e-05	0.000291	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ESR1—ovarian cancer	1.38e-05	0.000291	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL6ST—ovarian cancer	1.38e-05	0.000291	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—HRAS—ovarian cancer	1.38e-05	0.000289	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—PIK3CA—ovarian cancer	1.37e-05	0.000288	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—MAPK3—ovarian cancer	1.36e-05	0.000286	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL6ST—ovarian cancer	1.36e-05	0.000286	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—KRAS—ovarian cancer	1.36e-05	0.000285	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CXCL8—ovarian cancer	1.35e-05	0.000283	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CG—ovarian cancer	1.33e-05	0.000279	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—APC—ovarian cancer	1.33e-05	0.000279	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—NRAS—ovarian cancer	1.33e-05	0.000279	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—FASN—ovarian cancer	1.32e-05	0.000277	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—APC—ovarian cancer	1.31e-05	0.000275	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CG—ovarian cancer	1.31e-05	0.000275	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—NRAS—ovarian cancer	1.31e-05	0.000275	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CAV1—ovarian cancer	1.3e-05	0.000273	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—SLC5A5—ovarian cancer	1.3e-05	0.000272	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—MAPK1—ovarian cancer	1.3e-05	0.000272	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—EGFR—ovarian cancer	1.3e-05	0.000272	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CG—ovarian cancer	1.29e-05	0.000271	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL2—ovarian cancer	1.29e-05	0.00027	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TERT—ovarian cancer	1.28e-05	0.000269	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—MAPK3—ovarian cancer	1.27e-05	0.000267	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	1.26e-05	0.000264	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—MAPK3—ovarian cancer	1.25e-05	0.000263	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—SLC2A1—ovarian cancer	1.25e-05	0.000263	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CD—ovarian cancer	1.25e-05	0.000263	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—PIK3CA—ovarian cancer	1.25e-05	0.000262	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—PIK3CA—ovarian cancer	1.24e-05	0.00026	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CAV1—ovarian cancer	1.23e-05	0.000258	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.23e-05	0.000258	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—KRAS—ovarian cancer	1.23e-05	0.000257	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—ERBB2—ovarian cancer	1.22e-05	0.000257	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CB—ovarian cancer	1.22e-05	0.000256	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—AKT1—ovarian cancer	1.22e-05	0.000255	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—MAPK1—ovarian cancer	1.21e-05	0.000254	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—EGFR—ovarian cancer	1.21e-05	0.000254	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CB—ovarian cancer	1.21e-05	0.000254	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MTOR—ovarian cancer	1.21e-05	0.000254	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP1B1—ovarian cancer	1.2e-05	0.000252	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—MAPK1—ovarian cancer	1.19e-05	0.00025	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—EGFR—ovarian cancer	1.19e-05	0.00025	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CG—ovarian cancer	1.19e-05	0.000249	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CAV1—ovarian cancer	1.19e-05	0.000249	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.17e-05	0.000246	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CD—ovarian cancer	1.17e-05	0.000246	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ABCB1—ovarian cancer	1.17e-05	0.000245	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CXCL8—ovarian cancer	1.16e-05	0.000244	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—PIK3CA—ovarian cancer	1.16e-05	0.000243	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—HRAS—ovarian cancer	1.15e-05	0.000242	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CD—ovarian cancer	1.15e-05	0.000242	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—TYMS—ovarian cancer	1.15e-05	0.000241	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—KRAS—ovarian cancer	1.14e-05	0.00024	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ESR1—ovarian cancer	1.14e-05	0.00024	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—PIK3CA—ovarian cancer	1.14e-05	0.000239	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CD—ovarian cancer	1.14e-05	0.000238	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CDKN1B—ovarian cancer	1.13e-05	0.000238	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—KRAS—ovarian cancer	1.13e-05	0.000237	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—PIK3CA—ovarian cancer	1.13e-05	0.000236	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL6ST—ovarian cancer	1.12e-05	0.000236	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—AKT1—ovarian cancer	1.12e-05	0.000236	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CG—ovarian cancer	1.12e-05	0.000235	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CASP3—ovarian cancer	1.11e-05	0.000233	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL2—ovarian cancer	1.11e-05	0.000233	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ERBB2—ovarian cancer	1.11e-05	0.000232	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—IL6—ovarian cancer	1.1e-05	0.000232	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MTOR—ovarian cancer	1.09e-05	0.000229	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CB—ovarian cancer	1.09e-05	0.000229	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCND1—ovarian cancer	1.08e-05	0.000227	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—APC—ovarian cancer	1.08e-05	0.000227	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CG—ovarian cancer	1.08e-05	0.000227	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—NRAS—ovarian cancer	1.08e-05	0.000227	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CTNNB1—ovarian cancer	1.07e-05	0.000225	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	1.07e-05	0.000224	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.06e-05	0.000223	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTEN—ovarian cancer	1.05e-05	0.000221	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—PIK3CA—ovarian cancer	1.05e-05	0.000221	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MMP9—ovarian cancer	1.05e-05	0.000221	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CXCL8—ovarian cancer	1.05e-05	0.00022	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PTEN—ovarian cancer	1.04e-05	0.000219	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CD—ovarian cancer	1.04e-05	0.000219	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—HRAS—ovarian cancer	1.04e-05	0.000219	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—PIK3CA—ovarian cancer	1.03e-05	0.000217	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—MAPK3—ovarian cancer	1.03e-05	0.000217	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ERBB2—ovarian cancer	1.03e-05	0.000217	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CDKN1B—ovarian cancer	1.02e-05	0.000215	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MTOR—ovarian cancer	1.02e-05	0.000214	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CB—ovarian cancer	1.02e-05	0.000214	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—AKT1—ovarian cancer	1.02e-05	0.000214	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ERBB2—ovarian cancer	1.02e-05	0.000213	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—AKT1—ovarian cancer	1.01e-05	0.000213	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CASP3—ovarian cancer	1e-05	0.000211	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CB—ovarian cancer	1e-05	0.000211	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MTOR—ovarian cancer	1e-05	0.000211	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL2—ovarian cancer	1e-05	0.00021	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—IL6—ovarian cancer	9.97e-06	0.000209	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CB—ovarian cancer	9.9e-06	0.000208	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ABCB1—ovarian cancer	9.89e-06	0.000208	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—MAPK1—ovarian cancer	9.84e-06	0.000207	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—EGFR—ovarian cancer	9.84e-06	0.000207	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CD—ovarian cancer	9.83e-06	0.000206	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CXCL8—ovarian cancer	9.79e-06	0.000206	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCND1—ovarian cancer	9.76e-06	0.000205	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—HRAS—ovarian cancer	9.73e-06	0.000204	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—TYMS—ovarian cancer	9.71e-06	0.000204	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CTNNB1—ovarian cancer	9.67e-06	0.000203	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CXCL8—ovarian cancer	9.63e-06	0.000202	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—HRAS—ovarian cancer	9.57e-06	0.000201	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDKN1B—ovarian cancer	9.56e-06	0.000201	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CD—ovarian cancer	9.49e-06	0.000199	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MMP9—ovarian cancer	9.48e-06	0.000199	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—AKT1—ovarian cancer	9.46e-06	0.000199	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—VEGFA—ovarian cancer	9.43e-06	0.000198	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PTEN—ovarian cancer	9.42e-06	0.000198	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDKN1B—ovarian cancer	9.41e-06	0.000198	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—PIK3CA—ovarian cancer	9.4e-06	0.000198	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CASP3—ovarian cancer	9.37e-06	0.000197	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL2—ovarian cancer	9.36e-06	0.000197	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—STAT3—ovarian cancer	9.34e-06	0.000196	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NRAS—ovarian cancer	9.31e-06	0.000196	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—IL6—ovarian cancer	9.31e-06	0.000196	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—AKT1—ovarian cancer	9.31e-06	0.000196	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—KRAS—ovarian cancer	9.29e-06	0.000195	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CAV1—ovarian cancer	9.24e-06	0.000194	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CASP3—ovarian cancer	9.22e-06	0.000194	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL2—ovarian cancer	9.21e-06	0.000193	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—AKT1—ovarian cancer	9.19e-06	0.000193	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—IL6—ovarian cancer	9.16e-06	0.000192	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCND1—ovarian cancer	9.12e-06	0.000192	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CB—ovarian cancer	9.09e-06	0.000191	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CTNNB1—ovarian cancer	9.03e-06	0.00019	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCND1—ovarian cancer	8.98e-06	0.000189	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MAPK3—ovarian cancer	8.92e-06	0.000187	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CTNNB1—ovarian cancer	8.89e-06	0.000187	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MMP9—ovarian cancer	8.85e-06	0.000186	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PTEN—ovarian cancer	8.8e-06	0.000185	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MMP9—ovarian cancer	8.71e-06	0.000183	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MYC—ovarian cancer	8.67e-06	0.000182	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PTEN—ovarian cancer	8.66e-06	0.000182	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—AKT1—ovarian cancer	8.59e-06	0.00018	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CB—ovarian cancer	8.57e-06	0.00018	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTEN—ovarian cancer	8.55e-06	0.00018	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	8.54e-06	0.000179	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—VEGFA—ovarian cancer	8.51e-06	0.000179	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MAPK1—ovarian cancer	8.49e-06	0.000178	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EGFR—ovarian cancer	8.48e-06	0.000178	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	8.45e-06	0.000178	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—STAT3—ovarian cancer	8.43e-06	0.000177	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	8.42e-06	0.000177	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	8.41e-06	0.000177	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	8.38e-06	0.000176	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	8.27e-06	0.000174	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	8.27e-06	0.000174	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	8.05e-06	0.000169	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—KRAS—ovarian cancer	8.02e-06	0.000168	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	7.95e-06	0.000167	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	7.95e-06	0.000167	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	7.9e-06	0.000166	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	7.87e-06	0.000165	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	7.85e-06	0.000165	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTEN—ovarian cancer	7.85e-06	0.000165	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MYC—ovarian cancer	7.83e-06	0.000165	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CAV1—ovarian cancer	7.83e-06	0.000164	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	7.83e-06	0.000164	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	7.77e-06	0.000163	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	7.75e-06	0.000163	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	7.73e-06	0.000162	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	7.68e-06	0.000161	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	7.66e-06	0.000161	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	7.66e-06	0.000161	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	7.61e-06	0.00016	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL2—ovarian cancer	7.6e-06	0.00016	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	7.56e-06	0.000159	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	7.52e-06	0.000158	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	7.48e-06	0.000157	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CA—ovarian cancer	7.43e-06	0.000156	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	7.41e-06	0.000156	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTEN—ovarian cancer	7.4e-06	0.000156	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	7.4e-06	0.000155	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	7.4e-06	0.000155	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CA—ovarian cancer	7.36e-06	0.000155	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	7.34e-06	0.000154	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MYC—ovarian cancer	7.32e-06	0.000154	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	7.24e-06	0.000152	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MYC—ovarian cancer	7.2e-06	0.000151	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	7.19e-06	0.000151	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	7.16e-06	0.00015	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	7.16e-06	0.00015	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	7.15e-06	0.00015	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CG—ovarian cancer	7.13e-06	0.00015	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—ovarian cancer	7.12e-06	0.00015	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	7.04e-06	0.000148	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	7.04e-06	0.000148	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	6.98e-06	0.000147	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HRAS—ovarian cancer	6.81e-06	0.000143	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	6.76e-06	0.000142	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	6.65e-06	0.00014	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	6.65e-06	0.00014	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL6—ovarian cancer	6.52e-06	0.000137	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	6.46e-06	0.000136	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	6.45e-06	0.000135	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—ovarian cancer	6.43e-06	0.000135	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	6.39e-06	0.000134	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	6.38e-06	0.000134	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CD—ovarian cancer	6.27e-06	0.000132	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	6.21e-06	0.00013	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	6.15e-06	0.000129	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	6.11e-06	0.000128	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	6.11e-06	0.000128	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—AKT1—ovarian cancer	6.07e-06	0.000127	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CA—ovarian cancer	6.03e-06	0.000127	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—AKT1—ovarian cancer	6.02e-06	0.000126	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—ovarian cancer	6.01e-06	0.000126	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MYC—ovarian cancer	5.94e-06	0.000125	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—ovarian cancer	5.91e-06	0.000124	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL6—ovarian cancer	5.89e-06	0.000124	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	5.81e-06	0.000122	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	5.81e-06	0.000122	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	5.75e-06	0.000121	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	5.65e-06	0.000119	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTEN—ovarian cancer	5.57e-06	0.000117	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CA—ovarian cancer	5.54e-06	0.000116	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL6—ovarian cancer	5.5e-06	0.000116	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	5.49e-06	0.000115	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CB—ovarian cancer	5.46e-06	0.000115	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	5.43e-06	0.000114	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL6—ovarian cancer	5.41e-06	0.000114	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CA—ovarian cancer	5.22e-06	0.00011	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	5.07e-06	0.000107	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	5.04e-06	0.000106	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	4.99e-06	0.000105	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—AKT1—ovarian cancer	4.93e-06	0.000104	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—ovarian cancer	4.88e-06	0.000103	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTEN—ovarian cancer	4.72e-06	9.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	4.67e-06	9.8e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—AKT1—ovarian cancer	4.53e-06	9.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL6—ovarian cancer	4.47e-06	9.38e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—AKT1—ovarian cancer	4.27e-06	8.96e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	4.12e-06	8.66e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	3.93e-06	8.26e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CA—ovarian cancer	3.33e-06	7e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—AKT1—ovarian cancer	3.21e-06	6.75e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—AKT1—ovarian cancer	2.72e-06	5.71e-05	CbGpPWpGaD
